

Idelalisib Market

Market Report | 2025-05-01 | 257 pages | Datastring Consulting

AVAILABLE LICENSES:

- Multi User License \$1399.00

Report description:

Description

The market, for Idelalisib was estimated at \$689.5 million in 2024; and it is anticipated to increase to \$1.2 billion by 2030 with projections indicating a growth to around \$1.8 billion by 2035. This expansion represents a compound annual growth rate (CAGR) of 9.1% over the forecast period.

Segmentation

To see report segmentation please view the table of contents, or ask us for samples.

Table of Contents:

Chapter 1: Executive Summary - Major Markets & Their Performance - Statistical Snapshots

Chapter 2: Research Methodology

2.1: Axioms & Postulates

2.2: Market Introduction & Research Methodology - Estimation & Forecast Parameters / Major Databases & Sources

Chapter 3: Market Dynamics

3.1: Market Overview - Drivers / Restraints / Opportunities / M4 Factors

3.2: Market Trends

3.2.1: Introduction & Narratives

3.2.2: Market Trends - Impact Analysis (Short, Medium & Long Term Impacts)

3.3: Supply Chain Analysis

3.4: Porter's Five Forces - Suppliers & Buyers' Bargaining Power, Threat of Substitution & New Market Entrants, Competitive Rivalry

Chapter 4: Global Idelalisib Market Size, Opportunities & Strategic Insights, by Therapeutic Applications

4.1: Chronic Lymphocytic Leukemia

4.2: Follicular Lymphoma

4.3: Small Lymphocytic Lymphoma

4.4: Non-Hodgkin's Lymphoma

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

4.5: Others

Chapter 5: Global Idelalisib Market Size, Opportunities & Strategic Insights, by End Users

5.1: Hospitals

5.2: Oncology Clinics

5.3: Research Institutes

Chapter 6: Global Idelalisib Market Size, Opportunities & Strategic Insights, by Distribution Channels

6.1: Retail Pharmacies

6.2: Hospital Pharmacies

6.3: Online Pharmacies

Chapter 7: Idelalisib Market, by Region

7.1: North America Idelalisib Market Size, Opportunities, Key Trends & Strategic Insights

7.1.1: U.S.

7.1.2: Canada

7.2: Europe Idelalisib Market Size, Opportunities, Key Trends & Strategic Insights

7.2.1: Germany

7.2.2: France

7.2.3: UK

7.2.4: Italy

7.2.5: The Netherlands

7.2.6: Rest of EU

7.3: Asia Pacific Idelalisib Market Size, Opportunities, Key Trends & Strategic Insights

7.3.1: China

7.3.2: Japan

7.3.3: South Korea

7.3.4: India

7.3.5: Australia

7.3.6: Thailand

7.3.7: Rest of APAC

7.4: Middle East & Africa Idelalisib Market Size, Opportunities, Key Trends & Strategic Insights

7.4.1: Saudi Arabia

7.4.2: United Arab Emirates

7.4.3: South Africa

7.4.4: Rest of MEA

7.5: Latin America Idelalisib Market Size, Opportunities, Key Trends & Strategic Insights

7.5.1: Brazil

7.5.2: Mexico

7.5.3: Rest of LA

7.6: CIS Idelalisib Market Size, Opportunities, Key Trends & Strategic Insights

7.6.1: Russia

7.6.2: Rest of CIS

Chapter 8: Competitive Landscape

8.1: Competitive Dashboard & Market Share Analysis

8.2: Company Profiles (Overview, Financials, Developments, SWOT)

8.2.1: Gilead Sciences Inc.

8.2.2: Novartis AG

8.2.3: Pfizer Inc.

8.2.4: Roche Holding AG

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 8.2.5: Amgen Inc.
- 8.2.6: Johnson & Johnson
- 8.2.7: AbbVie Inc.
- 8.2.8: Bristol-Myers Squibb Co.
- 8.2.9: Merck & Co. Inc.
- 8.2.10: AstraZeneca Plc
- 8.2.11: Eli Lilly and Company
- 8.2.12: Sanofi S.A.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Idelalisib Market

Market Report | 2025-05-01 | 257 pages | Datastring Consulting

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Multi User License	\$1399.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-06-07"/>
		Signature	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com